EGFR and head and neck squamous cell carcinoma: Cetuximab, an EGFR inhibitor, improves survival in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), with acceptable toxicity when combined with radiotherapy or chemotherapy (19).Nivolumab, a PD-1 inhibitor, substantially prolongs survival in platinum-resistant patients, and its use in dual immunotherapy or in combination with EGFR inhibitors has demonstrated synergistic potential (20).